ZA200201567B - Pyrrolo[2,3-d]pyrimidine nucleoside analogs. - Google Patents
Pyrrolo[2,3-d]pyrimidine nucleoside analogs. Download PDFInfo
- Publication number
- ZA200201567B ZA200201567B ZA200201567A ZA200201567A ZA200201567B ZA 200201567 B ZA200201567 B ZA 200201567B ZA 200201567 A ZA200201567 A ZA 200201567A ZA 200201567 A ZA200201567 A ZA 200201567A ZA 200201567 B ZA200201567 B ZA 200201567B
- Authority
- ZA
- South Africa
- Prior art keywords
- cell
- compound
- cytokine
- group
- pyrrolo
- Prior art date
Links
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 title description 50
- 239000002718 pyrimidine nucleoside Substances 0.000 title description 20
- 150000001875 compounds Chemical class 0.000 claims description 129
- 210000004027 cell Anatomy 0.000 claims description 97
- 238000000034 method Methods 0.000 claims description 48
- 102000004127 Cytokines Human genes 0.000 claims description 46
- 108090000695 Cytokines Proteins 0.000 claims description 46
- 239000000203 mixture Substances 0.000 claims description 39
- 239000002777 nucleoside Substances 0.000 claims description 33
- 229910052739 hydrogen Inorganic materials 0.000 claims description 28
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 27
- 238000002360 preparation method Methods 0.000 claims description 25
- 230000028327 secretion Effects 0.000 claims description 22
- 125000003342 alkenyl group Chemical group 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 125000000304 alkynyl group Chemical group 0.000 claims description 18
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 16
- 230000003463 hyperproliferative effect Effects 0.000 claims description 16
- 206010060862 Prostate cancer Diseases 0.000 claims description 15
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 125000005842 heteroatom Chemical group 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 125000000524 functional group Chemical group 0.000 claims description 13
- 230000012010 growth Effects 0.000 claims description 12
- 239000003102 growth factor Substances 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 10
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 108090000978 Interleukin-4 Proteins 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 8
- 230000009467 reduction Effects 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 230000000873 masking effect Effects 0.000 claims description 6
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 230000006820 DNA synthesis Effects 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 10
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000004437 phosphorous atom Chemical group 0.000 claims 1
- 229910052698 phosphorus Chemical group 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 46
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 43
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 41
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- 239000000377 silicon dioxide Substances 0.000 description 19
- 239000000243 solution Substances 0.000 description 17
- 235000019439 ethyl acetate Nutrition 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 14
- 238000004587 chromatography analysis Methods 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 102000004890 Interleukin-8 Human genes 0.000 description 9
- 108090001007 Interleukin-8 Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 9
- 229940096397 interleukin-8 Drugs 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- NVJFFHZJCFOMTJ-UHFFFAOYSA-N 4-amino-6-bromo-7h-pyrrolo[2,3-d]pyrimidine-5-carbonitrile Chemical compound NC1=NC=NC2=C1C(C#N)=C(Br)N2 NVJFFHZJCFOMTJ-UHFFFAOYSA-N 0.000 description 7
- 229910052786 argon Inorganic materials 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical class CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000009833 condensation Methods 0.000 description 6
- 230000005494 condensation Effects 0.000 description 6
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000006188 syrup Substances 0.000 description 6
- 235000020357 syrup Nutrition 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 125000003835 nucleoside group Chemical group 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- -1 -modified pyrrolopyrimidine nucleoside Chemical class 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 229940125846 compound 25 Drugs 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 235000010288 sodium nitrite Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 241001364096 Pachycephalidae Species 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 2
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940127271 compound 49 Drugs 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 150000004943 pyrrolo[2,3-d]pyrimidines Chemical class 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- XOKJUSAYZUAMGJ-WOUKDFQISA-N toyocamycin Chemical compound C1=C(C#N)C=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O XOKJUSAYZUAMGJ-WOUKDFQISA-N 0.000 description 2
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- XUGWUUDOWNZAGW-VDAHYXPESA-N (1s,2r,5r)-5-(6-aminopurin-9-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1C=C(CO)[C@@H](O)[C@H]1O XUGWUUDOWNZAGW-VDAHYXPESA-N 0.000 description 1
- BIXYYZIIJIXVFW-UUOKFMHZSA-N (2R,3R,4S,5R)-2-(6-amino-2-chloro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O BIXYYZIIJIXVFW-UUOKFMHZSA-N 0.000 description 1
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- PNHBRYIAJCYNDA-VQCQRNETSA-N (4r)-6-[2-[2-ethyl-4-(4-fluorophenyl)-6-phenylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(CC)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 PNHBRYIAJCYNDA-VQCQRNETSA-N 0.000 description 1
- UXKLQDCALAWFIU-VKNDCNMPSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-tetradecoxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCCCC)C1=CC=CC=C1 UXKLQDCALAWFIU-VKNDCNMPSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- QLVGHFBUSGYCCG-UHFFFAOYSA-N 2-amino-n-(1-cyano-2-phenylethyl)acetamide Chemical compound NCC(=O)NC(C#N)CC1=CC=CC=C1 QLVGHFBUSGYCCG-UHFFFAOYSA-N 0.000 description 1
- HCLQARMRCPEALF-DNQXCXABSA-N 3-[[(2r)-2-[(1r)-2-[[1-(1-benzothiophen-2-yl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]pyrrolidin-1-yl]methyl]benzonitrile Chemical compound C([C@@H]1[C@H](O)CNC(C)(CC=2SC3=CC=CC=C3C=2)C)CCN1CC1=CC=CC(C#N)=C1 HCLQARMRCPEALF-DNQXCXABSA-N 0.000 description 1
- OVDGUTHABMXVMI-UHFFFAOYSA-N 3-nitro-4-(propylamino)benzoic acid Chemical compound CCCNC1=CC=C(C(O)=O)C=C1[N+]([O-])=O OVDGUTHABMXVMI-UHFFFAOYSA-N 0.000 description 1
- RXCVUHMIWHRLDF-HXUWFJFHSA-N 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one Chemical compound ClC1=C2CCN(C(C2=C(C(=C1)[C@@H](C1COC1)OC)Cl)=O)CC=1C(NC(=CC=1OC)C)=O RXCVUHMIWHRLDF-HXUWFJFHSA-N 0.000 description 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
- GDYUNCUMRKXRHY-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine-5-carbonitrile Chemical compound N1C=NC=C2C(C#N)=CN=C21 GDYUNCUMRKXRHY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000005234 Adenosylhomocysteinase Human genes 0.000 description 1
- 108020002202 Adenosylhomocysteinase Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- ULXPWOPOTSWJNN-RKEPMNIXSA-N C(#C)C1(O)[C@H](O)[C@H](O)[C@H](O1)CO Chemical compound C(#C)C1(O)[C@H](O)[C@H](O)[C@H](O1)CO ULXPWOPOTSWJNN-RKEPMNIXSA-N 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Natural products C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- KCTZOTUQSGYWLV-UHFFFAOYSA-N N1C=NC=C2N=CC=C21 Chemical compound N1C=NC=C2N=CC=C21 KCTZOTUQSGYWLV-UHFFFAOYSA-N 0.000 description 1
- TZCCKCLHNUSAMQ-DUGSHLAESA-N NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N Chemical compound NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N TZCCKCLHNUSAMQ-DUGSHLAESA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- XOKJUSAYZUAMGJ-UHFFFAOYSA-N Toyocamycin Natural products C1=C(C#N)C=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O XOKJUSAYZUAMGJ-UHFFFAOYSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- NXEJETQVUQAKTO-ZBCCYFLUSA-N [(2r,3r,4r)-4,5-diacetyloxy-2-methyloxolan-3-yl] acetate Chemical compound C[C@H]1OC(OC(C)=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O NXEJETQVUQAKTO-ZBCCYFLUSA-N 0.000 description 1
- MJOQJPYNENPSSS-XQHKEYJVSA-N [(3r,4s,5r,6s)-4,5,6-triacetyloxyoxan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1CO[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O MJOQJPYNENPSSS-XQHKEYJVSA-N 0.000 description 1
- QMLKOYYGGNYWQS-PHOYRPBPSA-N [(3s,4r)-5-acetyloxy-3,4-dibenzoyloxy-2-(benzoyloxymethyl)oxolan-2-yl]methyl benzoate Chemical compound CC(=O)OC([C@@H]([C@@H]1OC(=O)C=2C=CC=CC=2)OC(=O)C=2C=CC=CC=2)OC1(COC(=O)C=1C=CC=CC=1)COC(=O)C1=CC=CC=C1 QMLKOYYGGNYWQS-PHOYRPBPSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002487 adenosine deaminase inhibitor Substances 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000006480 benzoylation reaction Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000014564 chemokine production Effects 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125796 compound 3d Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940125872 compound 4d Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000007256 debromination reaction Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000013538 functional additive Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
- LROBJRRFCPYLIT-UHFFFAOYSA-M magnesium;ethyne;bromide Chemical compound [Mg+2].[Br-].[C-]#C LROBJRRFCPYLIT-UHFFFAOYSA-M 0.000 description 1
- DQEUYIQDSMINEY-UHFFFAOYSA-M magnesium;prop-1-ene;bromide Chemical compound [Mg+2].[Br-].[CH2-]C=C DQEUYIQDSMINEY-UHFFFAOYSA-M 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- BKBMACKZOSMMGT-UHFFFAOYSA-N methanol;toluene Chemical compound OC.CC1=CC=CC=C1 BKBMACKZOSMMGT-UHFFFAOYSA-N 0.000 description 1
- ZBELDPMWYXDLNY-UHFFFAOYSA-N methyl 9-(4-bromo-2-fluoroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate Chemical compound C12=C3SC(C(=N)OC)=NC3=CC=C2N=CN=C1NC1=CC=C(Br)C=C1F ZBELDPMWYXDLNY-UHFFFAOYSA-N 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 230000031723 negative regulation of chemokine production Effects 0.000 description 1
- 230000024717 negative regulation of secretion Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- XUGWUUDOWNZAGW-UHFFFAOYSA-N neplanocin A Natural products C1=NC=2C(N)=NC=NC=2N1C1C=C(CO)C(O)C1O XUGWUUDOWNZAGW-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- KYPREUXQEYJYPR-UHFFFAOYSA-N pyrimidine-5-carboximidamide Chemical compound NC(=N)C1=CN=CN=C1 KYPREUXQEYJYPR-UHFFFAOYSA-N 0.000 description 1
- 150000004944 pyrrolopyrimidines Chemical class 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
- YKEGUYTXACKXKS-IRXDYDNUSA-N tert-butyl (1s,5s)-3-[5-methyl-6-(2-methylpyridin-3-yl)oxypyrimidin-4-yl]oxy-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound CC1=NC=CC=C1OC1=NC=NC(OC2C[C@@H]3CC[C@H](N3C(=O)OC(C)(C)C)C2)=C1C YKEGUYTXACKXKS-IRXDYDNUSA-N 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 239000003734 thymidylate synthase inhibitor Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000005490 tosylate group Chemical class 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
PYRROLOJ}2,3-d]PYRIMIDINE NUCLEOSIDE ANALOGS
The field of the invention is nucleoside analogs.
Nucleoside analogs have long been used as antimetabolites for treatment of cancers and viral infections. After entry into the cell. nucleoside analogs are frequently phosphorylated by nucleoside salvage pathways, in which the analogs are typically phosphorylated to the correspon- ding mono-, di-. and triphosphates. Among other intracellular destinations, triphosphorylated nucleoside analogs often are used as substrate for DNA or RNA polymerases and consequently incorporated into DNA or RNA. Where triphosphoryiated nucleoside analogs are strong polymerase inhibitors. they may induce premature termination of a nascent nucleic acid molecule. Where triphosphorylated nucleoside analogs are incorporated into nucleic acid replicates or transcripts, gene expression or disruption of function may result.
On a more cellular level, the nucleoside analogs can also interfere with the cell cycle, and especially desirable effects of nucleoside analogs include induction of apoptosis of cancer cells.
Furthermore, nucleoside analogs are also known to modulate certain immune responses.
Various nucleoside analogs with relatively potent anti-cancer activity are known in the art, For example. known drugs include thymidylate synthase inhibitors such as 5-fluorouridine. adenosine deaminase inhibitors. including 2-chloroadenosine, and neplanocin A. which is an inhibitor of S-adenosylhomocysteine hydrolase. However, all or almost all of the known nucleoside analogs also imply a threat to normal mammalian cells, primarily because these nucleoside analog's lack adequate selectivity between normal cells and tumor cells.
Unfortunately, lack of adequate selectivity is frequently associated with severe side effects. and therefore often limits the potential of such analog therapeutics.
Although there are various nucleoside analogs known in the art, all or almost all of them, suffer from one or more disadvantage. Therefore, there is still a need to provide improved methods and compositions for nucleoside analogs.
oo MY.300/ 22674
Attorney Reference No.: 330.48-PCT IPEA/US ~ 5 MAR 2001
The present invention is directed to nucleoside analogs with modifications on the sugar moieties of the pyrrolo[2,3-d]pyrimidine nucleoside analogs, which can significantly reduce the toxicity of the nucleoside analogs to the mammalian cells while they also provide significant cytotoxicity to cancer cells. These modifications include but are not limited to substitutions at the C4’ and C5’ positions of ribofuranose moieties. The present invention also demonstrates that certain pyrrolo[2,3-d]pyrimidine nucleoside analogs have desired immunomodulation effects, including enhancement of Type 1 cytokines such as IL-2 and suppression of Type 2 cytokines such as IL-4. These immunomodulation properties can be useful in anticancer, antiviral and autoimmune diseases, treating inflammation and preventing graft rejection. ® In one aspect of the inventive subject matter, the nucleoside analog is a pyrrolo[2,3]pyrimidine nucleoside having a structure according to the formula (I):
Xz
NN
Rs . x A ne
Ry Ry ~~ wherein A is O, S, or CH2; X is H, NH; or OH; Y is H, halogen or NH»; Z is selected from the ~1s group consisting of H, halogen, R, OH, OR, SH, SR, NH,, NHR, NR;, CN, C(O)NH,, COOH,
COOR, CH,NH,, C(=NOH)NH,, and C(=NH)NH,, where R is alkyl, alkenyl, alkynyl, or aralkyl;
R, and Rj; are independently selected from the group consisting of H, F, and OH; Ry is selected from the group consisting of a hydrogen, an alkyl, an alkenyl, an alkynyl, and an aralkyl, wherein
R4 optionally has at least one of a heteroatom and a functional group; Rs is H, OH, OP(O)(OH);, P(O)(OH),, OP(O)(OR"),, or P(O)(OR'),, wherein R' is a masking group; and Rs is selected from the group consisting of an alkyl, an alkenyl, an alkynyl, and an aralkyl, wherein Rs has at least two carbon atoms, and optionally has at least one of a heteroatom and a functional group.
In another aspect of the inventive subject matter, the nucleoside analog is a pyrrolo[2,3d]pyrimidine nucleoside having a structure according to the formula (II): 2
AMENDED SHEET
'JIUS 00722674
Attorney Reference No.: 330.48-PCT
IPEA/US = 6 MAR 2001 oz
CI
NY
N re ON (1m
Rs O
Ry
Rs Rp wherein Z is CN, C(O)NH,, C(=NH)NH,, or C(=NOH)NH; and R4 and Rs are independently selected from the group consisting of a hydrogen, an alkyl, an alkenyl, an alkynyl, and an aralkyl, wherein R, and Rs independently and optionally contain at least one of a heteroatom and a functional group; with the proviso that Rs and Rs are not together hydrogen.
In a further aspect of the inventive subject matter, contemplated compounds are utilized & to inhibit tumor growth or to modulate Type 1 and Type 2 cytokine, and chemokine production.
Various objects, features, aspects and advantages of the present invention will become more apparent from the following detailed description of preferred embodiments of the - 10 invention, along with the accompanying drawings. ) Brief Description of The Drawing
Fig. 1 is a first exemplary synthetic scheme of reactions included in the production of compounds according to the inventive subject matter. 33 15 Fig. 2 is a second exemplary synthetic scheme of reactions included in the production of compounds according to the inventive subject matter.
Fig.3 is a third exemplary synthetic scheme of reactions included in the production of compounds according to the inventive subject matter.
Fig. 4 is a fourth exemplary synthetic scheme of reactions included in the production of compounds according to the inventive subject matter.
Fig. 5 is a fifth exemplary synthetic scheme of reactions included in the production of compounds according to the inventive subject matter. 3
AMENDED SHEET
.US00/ 22674
Attorney Reference No.: 330.48-PCT | PE AUS A ~ 6 MAR 2001
Fig. 6 is a sixth exemplary synthetic scheme of reactions included in the production of compounds according to the inventive subject matter.
Fig. 7 depicts exemplary compounds according to the inventive subject matter.
Fig. 8A and 8B are graphs representing the effect of compounds according to the inventive subject matter on the expression of Type 1 and Type 2 cytokines, respectively.
Fig. 9 is a table indicating cytotoxicity of various compounds according to the inventive subject matter.
Fig. 10 is a table indicating rates of DNA synthesis in cells treated with of various compounds according to the inventive subject matter.
BD 10 Fig. 11 is a graph depicting the inhibition of VEGF release from human prostate cancer cells upon treatment with compounds according to the inventive subject matter.
Fig. 12 is a graph depicting the inhibition of IL-8 release from human prostate cancer - cells upon treatment with compounds according to the inventive subject matter. ) 15 Detailed DescriptionDetailed Description
Pyrrolo[2,3-d]pyrimidine nucleoside analogs according to the general formulae (I) and (II) were found to have various biological effects on normal and hyperproliferative cells.
Ty X 5, zZ
N“ | \
A N 0)
Rs
Rs’ A
Ry
R; Ry 4
AMENDED SHEET oo PG! TSUD/ 2401 4
Attorney Reference No.: 330.48-PCT IPEA/US ~ 6 MAR 2001 wherein A is O, S, or CH; X is H, NH; or OH; Y is H, halogen or NH; Z is selected from the group consisting of H, halogen, R, OH, OR, SH, SR, NH,, NHR, NR;, CN, C(O)NH,, COOH,
COOR, CH,NH,, C(=NOH)NH,, and C(=NH)NH,, where R is alkyl, alkenyl, alkynyl, or aralkyl;
R; and R; are independently selected from the group consisting of H, F, and OH; Ry is selected from the group consisting of a hydrogen, an alkyl, an alkenyl, an alkynyl, and an aralkyl, wherein
R, optionally has at least one of a heteroatom and a functional group; Rs is H, OH, OP(O)(OH),,
P(O)(OH),, OP(O)(OR"),, or P(O)(OR"),, wherein R' is a masking group; and Rs is selected from the group consisting of an alkyl, an alkenyl, an alkynyl, and an aralkyl, wherein Rs has at least two carbon atoms, and optionally has at least one of a heteroatom and a functional group.
It should be especially appreciated that the terms "alkyl", "alkenyl", "alkynyl", and "aralkyl" as used herein refer to both linear and branched species. With respect to the
J. substituents R;, and Rj, it should be appreciated that both R; and R3 may be independently &W directed to the a- or B-face. Furthermore, where the substituents on Cs are non-identical, substitution on Cs may result in an R- or S-chiral center. The term "heteroatom", as used herein, refers to non-carbon atoms in an organic molecule, and particularly contemplated heteroatoms - include halogens, nitrogen, oxygen, and sulfur. The term "functional group" as used herein refers to a reactive bond (e.g., double or triple bond) or reactive group (e.g., -OH, -SH, -NH,, -N3, -CN, : COOH, -CHO, -CONH,, etc.).
Particularly contemplated pyrrolo[2,3-d]pyrimidine nucleoside analogs are those according to formula (I) wherein Z is CN, C(O)NH,, or C(=NH)NH, , and wherein Rs has at 5 least two carbon atoms and is selected from the group consisting of an alkyl, an alkenyl, an alkynyl, and an aralkyl.
The pyrrolo[2,3-d]pyrimidine nucleoside analog according to formula (II) has the following structure:
QO z
Re. NON
Rs’ Oo =
Ry Ry 5
AMENDED SHEET wherein Z is CN, C(O)NH,, C(=NH)NH,, or C(=NOH)NH; and R, and Rs are independently selected from the group consisting of a hydrogen. an alkyl, an alkenyl. an alkynyl, and an aralkyl. wherein R4 and Rs independently and optionally contain at least one of a heteroatom and a functional group; with the proviso that R, and Rs are not together hydrogen; and wherein the remaining substituents are as defined in formula (I).
It should be appreciated. however, that compounds according to the inventive subject matter may also be in forms and formulations other than previously described. and especially contemplated forms include prodrug forms or otherwise modified forms in which contemplated molecules are chemically and/or enzymatically modified to improve pharmacological and/or pharmacodynamical properties, including higher specificity towards target organs. cells or subcellular compartments and increased half-life time in the organism.
For example. cholesterol adducts may be formed to increase target specificity towards the liver, or apolipoprotein adducts may be formed to enhance penetration of the modified drug across the blood brain barrier to the brain. In another example, receptor ligand complexes may be synthesized to target the modified drug to a particular cell expressing a receptor specific for the ligand. Alternatively, antibody or antibody fragment complexes may be formed to increase ‘ selective delivery of the modified drug to a subcellular location. There are many prodrug and modified forms known in the art, and particularly contemplated prodrug forms include prodrugs : described in U.S. Provisional Application 60/216418, filed 04/17/00, and incorporated herein by reference. In still further examples, charged or uncharged groups, lipophilic or polar groups may be added to contemplated molecules to increase the half-life time in serum or other target organs and/or cells. In further examples, it should be appreciated that the contemplated compounds. where phosphorylated at the Cs atom, may also be di-, or tri-phosphorylated, or incorporate a thiophosphate.
While it is generally preferred that contemplated compounds have a sugar moiety in the
D-configuration, it is also contemplated that the compounds may have a sugar moiety in the
L-configuration. Further stereochemical aspects especially include R and S configurations at the
Cs atom where appropriate. and it should be appreciated that the substituents in contemplated compounds may be directed to a or phase.
It should also be appreciated that contemplated compounds can be formulated in various formulations, including liquid, syrup or gel forms (e.g., for injection, ingestion, or topical administration) and solid forms (e.g., for ingestion, injection, or deposition in a body cavity). For example. where it is contemplated that compounds according to the inventive subject matter are instable in the gastric environment. injection of a preferably isotonic solution is particularly contemplated. Alternatively, intranasal application or inhalation of a liquid form may be appropriate to circumvent acid degradation. On the other hand. where contemplated compounds are known to be resistant to digestive degradation, contemplated forms may be administered in form of a syrup or tablet. Depending on the particular use. contemplated compounds may also be formulated for topical or transdermal applications. There are many more formulations known in the art. all of which are also contemplated suitable in conjunction with the inventive subject matter presented herein, and particularly contemplated formulations are described in "Drug
Products for Clinical Trials: An Intl. Guide to Formulation, Production, Quality Control" by
Donald C. Monkhouse and Christopher T. Rhodes (Editors); ISBN:082479852X.
It should still further be appreciated that contemplated compounds and formulations may include functional and non-functional additives. For example, where transcutaneous drug delivery is desired, skin penetration enhancers may be added. Alternatively, pharmaceuticals including cytostatic, antiviral, or immunomodulatory agents, may be added to synergistically or ) additively improve the function of contemplated compounds. Examples for non-functional additives include fillers. antioxidants, flavor, or color agents to enhance a particular quality of contemplated compounds.
With respect to the concentration of contemplated compounds, it is preferred that the concentration is in a range of approximately 1uM to about 100uM when measured at the site of action. However, and particularly where the affinity of contemplated compounds is below 1uM. appropriate concentrations may also be in the range of 999nM to 10nM, and less. On the other hand, where contemplated compounds exhibit relatively short half-life times, or have a high turnover, contemplated concentrations may be 0.1mM and 100mM, and more. Consequently, the dosage of contemplated compounds may vary significantly, but appropriate dosages can readily be determined in in vitro or animal experiments.
YLIIUS UT / 240k
Attorney Reference No.: 330.48-PCT IPEAUS 2 0 MAR 2001
Among the various biological effects of both 5'- and 4'-modified pyrrolopyrimidine nucleoside analogs, particularly significant biological effects include modulation of the Type 1 and Type 2 cytokine production, control of neoplastic conditions (i.e., reduction of DNA synthe- sis or reduction in cell growth), and reduction of chemokine and growth factor release as described below.
Consequently, a contemplated method of changing secretion of a cytokine from a cell may comprise a step in which a compound according to formula (I) is provided and has a further step in which the cell is presented with the compound according to formula (I) at a concentration
She effective to change the secretion of the cytokine. While all possible combinations of substituents in formula (I) are generally contemplated, particularly contemplated compounds are compounds according to formula (I) wherein Ry and Rs: are independently selected from the group consisting of a hydrogen, an alkyl, an alkenyl, an alkynyl, and an aralkyl, and wherein R4 and Rs independently and optionally contain at least one of a heteroatom and a functional group, with the remaining substituents as defined above in formula (I). In an alternative aspect, the compound employed to change the secretion of a cytokine from a cell may also be a compound according to the following structure: ® I {
NIP
HO OH wherein Z is CN, C(O)NH,, C(=NH)NH,, C(=NNH,)NH,, or -C(=NOH)NH,, and wherein Rs is
H, OH, OP(O)(OH),, P(O)(OH),, OP(O)(OR"),, or P(O)(OR"),, with R' being a masking group.
Contemplated cytokines particularly include Type 1 (e.g., IFNy) and Type 2 (e.g., IL-4) cytokines. With respect to the cells, it is contemplated that all cells known to produce and/or secrete cytokines are appropriate, however, especially contemplated cells include lymphocytes and cancer cells (e.g., prostate cancer cells, infra). ) 8
AMENDED SHEET
© WO 0127114 PCT/US00/22674
In a further aspect of the inventive subject matter. a method of reducing growth of a hyperproliferative cell may comprise a step in which a compound according to formula (I) is provided. and another step in which the hyperproliferative cell is presented with the compound at a concentration effective to reduce the growth of the hyperproliferative cell. Particularly preferred compounds include compounds according to formula (I) wherein Ry is selected from the group consisting of a hydrogen, an alkyl. an alkenyl, an alkynyl, and an aralkyl, wherein Ry optionally contains at least one of a heteroatom and a functional group. and wherein Ry is selected from the group consisting of a hydrogen, an alkyl. an alkenyl. an alkynyl. and an aralkyl. wherein Rs has at least two carbon atoms, and optionally contains at least one of a heteroatom and a functional group, with the proviso that R, and Rs are not together hydrogen, and with the remaining substituents as defined above in formula (I).
Particularly contemplated hyperproliferative cells include cancer cells. and an especially contemplated cancer cell is a prostate cancer cell. While not whishing to be bound to a particular theory, it is contemplated that the reduction of growth comprises reduction of DNA synthesis. } 15 In a still further aspect of the inventive subject matter, it is contemplated that a method of reducing a release of a growth factor from a cell has a step in which a compound according to formula (I) is provided, and another step in which the cell is presented with the compound at a concentration effective to reduce the release of the growth factor. It is contemplated that the release of various growth factors may be reduced by the method presented herein. however reduction of VEGF release is especially contemplated. Similarly. while all cells known to secrete growth factors are contemplated in conjunction with the method presented herein, particularly contemplated cells include cancer cells, and especially prostate cancer cells.
With respect to the synthesis of contemplated compounds, it should be appreciated that pyrrolo[2.3-d]pyrimidine nucleoside analogs according to the inventive subject matter can be synthesized via various synthetic routes. and the following procedures are provided by way of example only.
Synthesis of C5 -modified pyrrolo[2,3-d]pyrimidine nucleoside analogs
The 5’-substituted nucleoside analogs are prepared from the condensation of the pyrrolo(2,3-d]pyrimidine bases and the properly protected. 5’-substituted ribofuranoses. As shown in Figure 1. Compound 1, prepared according to a published procedure (Jones et al.
Methods in carbohydrate Chemistry (edited by Whistler and Moffat). vol. VI, pp315-322,
Academic Press. New York, (1972)), was treated with a variety of nucleophiles such as Grignard reagents to give compound 2, which was benzoylated and subsequently treated with trifluoroacetic acid to give compound 4. Benzoylation and the following treatment with acetic anhydride/acetic acid in the presence of sulfuric acid to give compound 6, which was used for condensation with pyrrolo[2.3-d]pyrimidine bases.
Compound 7 (Jones et al. Methods in carbohydrate Chemistry (edited by Whistler and
Moffat). vol. VI. pp315-322. Academic Press, New York. (1972)), prepared according to a published procedure. was converted to a tosylate derivative, which was reduced with lithium aluminum hydride to give compound 8. By similar procedures shown in Figure 1. compound 8 was converted to compound 9. The condensation of 9 and the pyrrolo[2.3-d]pyrimidine 19 and the subsequent transformations as shown in scheme 2 gave compounds 10-15 as illustrated in
Figure 2.
As shown in Figure 3, Compound 2 was converted to the sulfonate 16. which was subjected to nucleophilic replacement to give the configurationally inverted compound 17. Deprotection of the isopropylidene and the subsequent acetylation gave the tetraacetate 18.
Condensation of the 5-C-substituted, protected ribofuranoses with nucleoside bases is depicted in Figure 4. 5-Cyanopyrrolo[2,3-d]pyrimidine 19, prepared according to a published procedure (Tolman et al. J. Org. Chem. 1969, 91, 2102-2108), was converted to the trimethylsilyl derivative and then condensed with compound 6 in the presence of trimethylsilyl triflate by a similar procedure described for toyocamycin (Sharma et al. Nucleosides Nucleotides 1993, 12, 643-648). The resulting coupling product was subjected to debromination through hydrogenation to give compound 20. Treatment of 20 with ammonia in anhydrous methanol gave compounds 21 and 23. Compound 21 was oxidized to give compound 22. Compound 23 was converted to the carboxamide derivative 24. Compound 23 and 24 were oxidized to give compound 25.
Treatment of compound 25 with hydroxyamine yielded compound 26, which was hydrogenated
© WO 0127114 PCT/US00/22674 over Raney Nickel to give 27. Alternatively, compound 27 was also prepared by heating compound 25 with ammonia in a pressured bomb.
Synthesis of C4 -modified pyrrolo[2,3-d]pyrimidine nucleoside analogs
In Figure 5, compound 1 was treated with formaldehyde in aqueous sodium hydroxide to give 4’-hydroxymethyl derivative 28, which was selectively protected to afford compound 29.
The subsequent protection with DMT and removal of TBS gave compound 31. which can be converted to a variety of substituents. The 4-C-substituted derivatives subjected to similar transformations as 5-C-substituted ribofuranoses (scheme 1) can be converted to compound 35, which is used for condensation with nucleoside bases.
Similar to the C5’-substituted pyrrolopyrimidine nucleoiside analogs. the 4’-substituted analogs 36 can be obtained by condensation of compound 35 with compound 19 as depicted in
Figure 6. The subsequent transformations can give the 4’-C-substituted pyrrolopyrimidine nucleoside 37-42.
Synthesis of 2'-modified, and other pyrrolo[2,3-d[pyrimidine nucleoside analogs
The following pyrrolopyrimidine nucleoside analogs were prepared for biological testing, some of which were published (indicated as known compounds), and are shown in Figure 7.
The known compounds 43, 44, 52-55, and 57 were prepared according to a published procedure (Hinshaw et al. J. Org. Chem. 1970, 92, 236-241). Compound 56 was prepared by hydrogenation of compound 52. The known compound 49 (Krawczyk et al. Nucleosides Nucleotides 1989, §. 97-115) was treated with sodium nitrite to give compound 50. The known compounds 45 and 48 were prepared according to a published procedure (Ramasamy et al. J. Heterocyclic Chem. 1988, 25, 1043-1046). Compound 45 was treated with ammonia-methanol to give compound 46 and hydrogenated to give compound 47. Compounds 58-63 were prepared from compound 45 by similar procedures used for compounds 52-57. The known compound 64 (Krawczyk et al.
Nucleosides Nucleotides 1989, 8, 97-115) was converted to compounds 65-67. The known compound 68 (Ramasamy et al. Tetrahedron 1986, 42, 5869-5878) was converted to compounds 69 and 70.
Preparation of human T-cells and activation in vitro
Peripheral blood mononuclear cells were isolated from healthy donors by density gradient centrifugation followed by T cell enrichment using Lymphokwik (One Lambda, Canoga
Park CA). Contaminating monocytes were removed by adherence to plastic. Purified T cells were >99% CD2+,<1% HLA-DR+ and < 5% CD25+ and were maintained in RPMI-APS (RPMI1640 medium containing 5% autologous plasma, 1% L-glutamine, 1% penicillin/streptomycin and 0.05% 2-mercaptoethanol). For determination of cytokine protein levels, T-cells (0.2 x 10° cells in a volume of 0.2 ml) were activated by the addition of 2 ng phorbol myristate acetate plus 0.1 mg ionomycin (PMA-ION, both from Calbiochem, San Diego,
CA) and incubated in 96 well plates in the presence of 0 or 10 pM of various guanosine nucleosides for 48 h at 37°C. Following activation, supernatants were analyzed for cell-derived cytokine production.
Extracellular cytokine analyses.
Human cytokine levels were determined in cell supernatants, following appropriate dilution, using ELISA Kits specific for IFNy and IL-4 (Biosource, Camarillo, CA). All ELISA results were expressed as pg/ml. )
Effect of pyrrolo-[2.3,d]pyrimidine nucleoside analogs on extracellular cytokine levels in activated human T cells.
The effect of pyrrolo-[2,3-d]pyrimidine nucleoside analogs at 0 and 10 uM. on
PMA/ionomycin stimulated T cell expression of the Type 1 cytokine, IFNy, and the Type 2 cytokine. IL-4, is shown in Figures 8A and 8B for 5 individual human donors. Cytokine levels were determined in cell free supernatants by ELISA. The most potent effect was observed with 7-b-D-ribofuransyl-4-oxopyrrolo-[2,3-d] pyrimidine-5-carboxamidine. This compound enhanced activated IL-4 production by 498% + 83 and suppressed [FNy by 43% = 4 of the activated control levels of each cytokine. Data are shown as percentage of activated control calculated as the ratio of activated T cell cytokine level in the presence of test nucleosides over the cytokine jevel of untreated activated T cells x 100 %. Zero effect on cytokine levels by test nucleosides would give a percentage of activated control value of 100 %. The absolute level (pg/ml + standard deviation) of PMA-ION-induced cytokine secretion was for IFNy, 22954 + 3391; and for IL-4, 162 + 40. Resting levels were < 30 pg/ml for all cytokines tested.
woos PCT/US00/22674
Cytotoxicity of the pyrrolo[2,3-d]pyrimidine nucleoside analogs in vitro
The pyrrolo[2,3-d]pyrimidine nucleoside analogs of the present invention are bioactive since they indicate some level of cytotoxicity in vitro. In these studies, the compounds tested were applied to cell culture of normal human fibroblasts, human Prostate cancer cells 81, human
Melanoma cancer cells 140. Human Lung Cancer cells 177. and human Ovarian Cancer cells R and NR (all available from ATCC). In these experiments cells were plated at density of 2000 cells per 200ul of medium per well (96-well plate). The compounds tested were applied to the wells once, at concentration range 0.78-100uM, just after plating of cells. The colorimetric cytotoxicity assay MTS was performed after 72 hrs of treatment. EC50 was calculated based on readings collected and they are presented in Figure 9. Several compounds indicate lack of cytotoxicity in concentration below 100uM. In such cases EC50 is marked as >100. In other cases. EC50 indicates the concentration of the compound tested needed to damage 50% of cell population.
The pryrrolo[2,3-d]pyrimidine nucleoside analogs inhibit DNA synthesis in cells cultured in vitro in a dose-dependent manner
Analogs of pyrrolo[2,3-d]pyrimidine nucleoside inhibit growth of human celis cultured in vitro as measured by the level of DNA. The experimental setup was the same as described above. The compounds were given once and DNA level was measured after 72 hrs. At that time, half of the medium was removed from culture wells and replaced by pure water. After that, the cells were transferred to —70°C for at least 12 hrs. In the next step, cells were transferred back from —70°C to room temperature and 1 pM of Hoechst 33342 was given to each well. After 2 hrs of incubation, the fluorescence signal (360-530nm) was measured. According to this method, intensity of florescence is proportional to amount of DNA due to presence of DNA-Hoechst 33342 complex formed. The results are presented in Figure 10. The numbers express fold of
DNA amount increase compared to amount of DNA at the beginning of experiment (2 hrs after plating of cells). In the untreated prostate cancer cells and normal cells the DNA level increased 5.78 and 4.47 times, respectively, during 72 hrs of culture.
The compounds 23a(5’-R) and 23a(5 '-S) inhibit secretion of VEGF from Human Prostate
Cancer in vitro.
The compounds 23a(5’-R) and 23a(5°-S) are potent in inhibition of secretion of Vascular
Endothelial Growth Factor (VEGF) from Human Prostate cancer cells, HTB81. VEGF is recognized as angiogenesis marker since this molecule is crucial for migration and growth of endothelial cells and microvessel formation in vivo. In order to prove this. 0.5x10° of the cells were plated in 5 ml of culture medium into a 10cm diameter petri dish. The compounds were applied just after plating for 72 hrs. After that, the medium was collected and the level of VEGF was measured using VEGF Elisa Assay (R&D Systems) and expressed as pg of VEGF per ml of the medium. The results are presented in Figure 11. According to these results, both compounds inhibit secretion of VEGF in a dose-dependent manner.
The compounds 23a(5’-R) and 23a(5'-S) inhibit release of IL-8 from human prostate cancer cells cultured in vitro.
The compound 23a(5’-R) and 23a(5°-S) indicate an inhibitory effect on secretion of
Interleukin-8 (IL-8) from human prostate cancer cells. HTB81. IL-8 belongs to the class of chemo-attractant chemokines (type alpha), which are involved in inflammation processes due to attraction of neutrophils. Chemokines. in general. are known to be produced by various types of cancer. It is proven in several studies that inhibition of chemokine production by cancer cells is beneficial for the host. In order to prove the potency of these two compounds to inhibit IL-8 secretion from prostate cancer cells, prostate cancer cells HTB 81 were treated in vitro with compounds 23a in both the 5'-R and 5'-S configuration at concentrations indicated in the graph.
The medium collected from the culture was analyzed for IL-8 level using IL-8 Elisa Assay from
R&D Systems. According to the results collected, both compounds are able to inhibit secretion of IL-8 in a dose-dependent manner, as depicted in Figure 12.
It should be appreciated, however, that the biological effects of contemplated compounds need not be limited to the particular effects as described above. In particular. it is contemplated that the compounds according to the inventive subject matter generally exhibit cytostatic effect in various hyperproliferative disorders, including localized and/or metastatic cancers (e.g, , lymphomas and carcinomas), benign prostate hyperplasia, and keratoses. While the inventors found substantial biological effects on IL-4 (a Type 2 cytokine) and IFNy (a Type 1 cytokine), it is generally contemplated that the compounds according to the inventive subject matter are biologically active in modulation of cytokines other than IL-4 and IFN-y. It is especially contemplated that the compounds may increase or decrease the expression/secretion of a particular cytokine or set of cytokines. Therefore, it is contemplated that compounds according to the inventive subject matter may modulate the immune system of an organism such that a more pronounced Type 1 or Type 2 response may be achieved. Consequently, it is contemplated that the compounds according to the inventive subject matter may be effective to reduce the titer of a virus in a living system by either direct action as inhibitor of a viral polymerase and/or indirectly by activating the immune system to a particular humoral or cellular response. It is further contemplated that compounds according to the inventive subject matter may also be useful in reducing a response of an immune system towards an allo- or xenograft by reducing the severity of the cellular reponse towards the allo- or xenograft.
The following protocols describe an exemplary synthesis of various compounds according to the inventive subject matter and are intended only to illustrate but not to limit the inventive concept presented herein.
Preparation of methyl 2, 3-O-isopropylidene-5(R,S)-C-ethynyl--ribofuranoside (2b)
To a stirred solution of methyl 4-C,5-0O-didehydro-2,3-O-isopropylidene-B-D-ribo- furanoside (Jones et al. Methods in Carbohydrate Chemistry Vol 1, pp315-322 (1972), 4.00 g, 19.78 mmol) in anhydrous THF (20 mL) at -42 °C under argon was added dropwise ethynylmagnesium bromide (0.5 M in THF, 80 mL, 40 mmol). Upon addition, the resulting mixture was slowly warmed up to 0 °C (~90 min.). The reaction was quenched by adding ice (50 g)/water (50 mL) and the mixture was stirred for 30 min. After neutralization with 10 % aq. acetic acid, the mixture was extracted with ethyl acetate twice. The combined organic layer was dried (Na,SO,) and concentrated. Chromatography on silica (ethyl acetate-hexanes 1:4) gave 3.48 g of the titled compound (R/S ratio 1:1) as a white solid. The following compounds were prepared in a similar fashion: Methyl 2,3-O-isopropylidene-5(R)-C-methyl-p-D-ribofuranoside (2a) was prepared from methyl 4-C,5-O-dihehydro-2,3-O-isopropylidene-B-D-ribofuranoside and ethylmagnesium bromide. Methyl 2,3-O-isopropylidene-5(R)-C-vinyl-B-D-ribofuranoside (2c) was prepared from methyl 4-C,5-O-dihehydro-2,3-O-isopropylidene-B-D-ribofuranoside and vinylmagnesium bromide. Methyl 5(R)-C-allyl-2,3-O-isopropylidene-f-D-ribofuranoside (2d) was prepared from methyl 4-C,5-O-dihehydro-2,3-O-isopropylidene-B-D-ribofuranoside and allylmagnesium bromide.
Preparation of methyl 2,3-O-isoproplidene-35-O-methanesulfonyl-5(R)-C-methyl- S-D- ribofuranoside (16)
To a stirred solution of methyl 2,3-O-isopropylidene-5(R)-C-methyl-B-D-ribofuranoside (2a, 7.24 g, 33.17 mmol) in anhydrous pyridine (50 mL) at 0 °C was added methanesulfonyl chloride (3.1 mL, 39.92 mmol). The resulting mixture was stirred at room temperature for 1 h, cooled to 0 °C, quenched by adding water (1.0 mL), and stirred at room temperature for 30 min.
The solvent was evaporated and the residue was dissolved in ethyl acetate, washed with brine three times, dried (Na;SO4) and concentrated. Chromatography on silica (30% EtOAc in hexanes) gave 8.62 g of the titled compound 16 as a colorless syrup.
Preparation of methyl 2,3-O-isopropylidene-5-0-acetyl-5(S)-C-methyl--D ribofuranoside (17)
A stirred suspension of methyl 2,3-O-isopropylidene-5-O-methanesulfonyl-5(R)-C- methyl-B-D-ribofuranoside (16, 8.62 g, 29.1 mmol) and NaOAc (anhydrous, 3.5 g, 42.5 mmol) in anhydrous DMF (350 mL) was heated at 125 °C under argon for 4 days. The solvent was evaporated and the residue chromatographed on silica (25% EtOAc in hexanes) to give 4.0 g of the titled compound 17 as a white solid. : Preparation of methyl 2,3-0-isopropylidene-4-C-hydroxymethyl-f-D-ribofuranoside (28)
To a stirred solution of methyl 4-C,5-0-didehydro-2,3-O-isopropylidene-3-D- ribofuranoside 1 (20.22 g, 100 mmol) in dioxane (380 mL) at 0 °C was added dropwise formaldehyde (37 % solution, 76 mL) and then 2 M NaOH (188 mL). The resulting reaction mixture was stirred at room temperature for 20 h, cooled to 0 °C, neutralized (10% acetic acid), concentrated (~50 %), and extracted with methylene chloride twice. The combined organic layer was dried (Na,SO.) and concentrated to dryness. Chromatography on silica (4 % methanol in chloroform) gave 20.2 g of the titled compound 28 as a white solid.
Preparation of methyl 2,3-0-isopropylidene-5-deoxy- -D-ribofuranoside (8)
To a stirred solution of methyl 2,3-O-isopropylidene-p-D-ribofuranoside (14.2 g, 70.0 mmol) in anhydrous pyridine (250 mL) at 10 °C was added in portions (over 30 min) p- toluenesulfonyl chloride (19.1 g, 100 mmol). The resulting mixture was stirred at room temperature for 18 h, cooled to 0°C, quenched by adding water (5.0 mL), and stirred at room temperature for 30 min. The solvent was evaporated. The residue was dissolved in ethyl acetate,
washed with brine three times. dried (Na,SO,) and concentrated to dryness. Chromatography on silica (ethyl acetate-hexanes 1:3) gave 24.1 g of the titled compound as a white solid.
To a stirred suspension of LiAlH, (4.58 g, 120.5 mmol) in anhydrous diethyl ether (120 mL) was added methyl 2,3-O-isopropylidene-5-O-p-toluenesulfonyl-f-D-ribofuranoside (13.1 ¢, 36.55 mmol) in diethyl ether-toluenc (2.5:1, 140 mL). The resulting mixture was refluxed for 22 h. cooled to room temperature, diluted with ethyl acetate (25 mL) quenched by adding water (5.0 mL). The solvent was evaporated. The residue was dissolved in ethyl acetate. washed with brine three times. dried (Na;SO,) and concentrated to dryness. Chromatography on silica (ethyl acetate hexanes 1:3) gave 3.58 g of the titled compound as a colorless liquid.
Preparation of methyl 5(R)-C-allyl-5-O-benzoyl-2, 3-O-isopropylidene-B-D-ribofuranoside (3d)
To a stirred solution of methyl 5(R)-C-allyl-2.3-O-isoproplidene-B-D-ribofuranoside (4.49 g, 18.38 mmol) in anhydrous pyridine (40 mL) at 0 °C was added benzoyl chloride (2.7 mL, 23.0 mmol). The resulting mixture was stirred at room temperature for 18 h, cooled with ice, quenched by adding water (1 mL), and stirred at room temperature for 30 min. The solvent was evaporated and the residue was dissolved in ethyl acetate, washed with brine three times, dried (Na,SO4) and concentrated. Chromatography on silica (12% ethyl acetate in hexanes) gave 6.26 g of the titled compound 3d as a colorless syrup. The following compounds were prepared in a similar fashion: Methyl 5-O-benzoyl-5(R,S)-C-ethynyl-2,3-O-isoproplidene-B-D-ribofurano- side (3b, R/S ratio: 1:1) from methyl 5(R.S)-C-ethynyl-2.3-O-isoproplidene-f-D-ribofuranoside (2b). Methyl 4-C-benzoyloxymethyl-5-0-benzoyl-2.3-O-isoproplidene-B-D-ribofuranoside from methyl 2.3-O-isoproplidene-4-C-hydroxymethyl-f-D-ribofuranoside.
Preparation of methyl 5(R)-C-allyl-5-0-benzoyl-S-D-ribofuranoside (4d)
A solution of methyl 5(R)-C-allyl-5-O-benzoyl-2.3-O-isopropylidene-p-D-ribofuranoside (3d, 6.2 g, 17.8 mmol) in TFA-H,O mixture (9:1) was stirred at 0 °C for 90 min and concentrated to dryness at 0°C. The residue was dissolved in methanol-toluene mixture (20 mL, 1:1) and concentrated to dryness. Chromatography on silica (ethyl acetate -hexanes 1:1) gave 3.70 g of the titled compound 4d as a white solid. The following compounds were prepared in a similar fashion: Methyl 5-O-benzoyl-5(R,S)-C-ethynyl-B-D-ribofuranoside (4b. R/S ratio: 1:1) from methyl 5-O-benzoyl-5(R,S)-C-ethynyl-2,3-O-isopropylidene-f-D-ribofuranoside (3b).
Methyl 5-O-benzoyi-4-C-benzoyloxymethyl-B-D-ribofuranoside from methyl 5-O-benzoyl-4-C- benzoyloxymethyl-2,3-O-isopropylidene-B-D-ribofuranoside.
Preparation of methyl 5(R)-C -allyl-2.3.5-tri-O-benzoyl-B-D-ribofuranoside (5d)
S To a stirred solution of methyl 5(R)-C-allyl-5-O-benzoyl-B-D-ribofuranoside (4d, 3.60mg, 11.68 mmol) in anhydrous pyridine (80 mL) at 0 °C was added benzoyl chloride (3.0 mL. 25.84 mmol). The resulting mixture was stirred at room temperature for 18 h, cooled with ice, quenched by adding water (1 mL), then stirred at room temperature for 30 min. The mixture was concentrated, diluted with ethyl acetate, washed with brine three times. dried (Na,S0O,) and concentrated to dryness. Chromatography on silica (15% ethyl acetate in hexanes) gave 5.3 g of the titled compound 5d as a colorless syrup. The following compounds were prepared in a similar fashion: Methyl 5(R,S)-C-ethyny!-2.3,5-tri-O-benzoyl-B-D-ribofuranoside (Sb, R/S ratio: 1:1) from methyl 5-O-benzolyl-5(R,S)-C-ethynyl-B-D-ribofuranoside (4b). Methyl 4-C-benzoyl- oxomethyl-2,3,5-tri-O-benzoyl-B-D-ribofuranoside from methyl 4-C-benzoyloxymethyl-5-0- benzoyl-B-D-ribofuranoside.
Preparation of 1-O-methyl-2, 3,5-tri-O-benzoyl-5(R)-C-vinyl-B-D-ribofuranose (Sc) -
A solution of methyl 2,3-O-isopropylidene-5(R)-C-vinyl-B-D-ribofuranosise (2c. 1.0 g, 4.3 mmol) in a mixture of trifluoroacetic acid and water (9:1, v/v, 11 mL) was strirred at 0 °C for ) 30 min and concentrated to dryness. The residue was dissolved in methanol and concentrated to dryness (3 times), then dissolved in pyridine and evaporated, and finally was dissolved in anhydrous pyridine (11 mL). To this solution was added benzoyl chloride (1.9 mL, 16 mmol).
The reaction mixture was stirred at 25 °C for 16 h and poured into ice water (20 mL). The mixture was extracted with dichloromethane (20 mL) and the organic layer was dried over sodium sulfate, and concentrated to dryness. The residue was chromatographed on silica (0-5% ethyl acetate in dichloromethane) to give 1.0 g of the titled compound 5c as a syrup.
Preparation of 1-O-acetyl-2,3,5-tri-O-benzoyl-5(R)-C-allyl-D-ribofuranose (6d)
To a stirred solution of methyl 5(R)-C-allyl-2,3,5-tri-O-benzolyl-B-D-ribofuranoside (54, 4.0 g, 7.74 mmol) in acetic acid (14 mL) and acetic anhydride (1.75 mL, 18.36 mmol) at 0 °C
) | WO 01/27114 PCT/US00/22674 was added concentrated sulfuric acid (200 pL. 3.79 mmol in 4.0 mL of acetic acid). The resulting mixture was stirred at room temperature for 20 h, cooled to 0 °C, diluted with cold cthyl acetate, washed with water, 5% aq. NaHCO; and then brine, dried (Na;SQ,), and concentrated. Chromatography on silica (ethyl acetate-hexanes 1:4) gave 2.82 g of the titled compound 6d (a/p ratio: 1:2) as a colorless foam. The following compounds were prepared in a similar fashion: 1-O-Acetyl-5(R,S)-C-ethynyl-2,3,5-tri-O-benzolyl-B-D-ribofuranose (6b, R/S ratio: 1:1 and o/ ratio: 1:2) from methyl 5(R,S)-C-ethynyl-2.3,5-tri-O-benzolyl-B-D- nibofuranoside (5b). 1-O-Acethyl-4-C-benzoyloxymethyl-2,3,5-tri-O-benzoyl-D-ribofuranose (o/ p ratio: 1:3) from methyl 4-C-benzoyloxymethyl-2,3,5-tri-O-benzoyl-B-D-ribofuranoside. 5(R)-
C-Methyl-1,2,3,5-tetra-O-acetyl-B-D-ribofuranose from methyl 2,3-O-isopropylidene-5(R)-C- methyl-B-D-ribofuranoside. 1.2,3,5-Tetra-O-acetyl-5(S)-C-methyl-D-ribofuranose 6a from methyl 5-O-acetyl-2.3-O- isopropylidene-5(R)-C-methyl-p-D-ribofuranoside. 5-deoxy-1,2,3-tri-O-acetyl-D-ribofuranose 9 from methyl 5-O-acetyl-2,3-O-isopropylidene-B-D-ribofuranoside. 1-O-Acetyl-2,3,5-tri-O- benzoyl-5(R)-C-vinyl-B-D-ribofuranose 6c from methyl 2,3,5-tri-O-benzoyl-5(R)-C-vinyl-B-D- ribofuranoside.
Preparation of 4-amino-6-bromo-3-cyano-7-(2,3,5-tri-O-benzoyl-5(R)-C-allyl--D- ribofuranosyl)pyrrolo(2,3-d]pyrimidine
A suspension of 4-amino-6-bromo-5-cyanopyrrolo[2,3-d]pyrimidine (Tolman et al. J.
Org. Chem. 1969, 91, 2102-2108, 1.05 g, 4.41 mmol) and ammonium sulfate (50 mg) in HMDS (75 mL) and anhydrous m-xylene (25 mL) was refluxed under argon for 18 h. Solvents were evaporated and the residue was dried under vacuum, The residue was dissolved in anhydrous 1,2-dichloroethane (80 mL) and mixed with 1-O-acetyl-2,3,5-tri-O-benzoyl-5(R)-C-allyl-D- ribofuranose (2.00 g, 3.67 mmol). Under cooling with ice, TMSOTf (1.3 mL, 7.30 mmol in § mL of anhydrous 1,2-dichloroethane) was added. The mixture under argon was stirred at room temperature for 30 min, then refluxed for 90 h, quenched by pouring it (cold) onto ice/NaHCO, (50 mL), and filtered. The organic layer was separated, dried (Na,SO,), and concentrated.
Chromatography on silica (EtOAc-hexanes 2:3) gave 1.81 g of the titled compound as a colorless solid. The following compounds were prepared in a similar fashion: 4-Amino-6- bromo-5-cyano-7-(2,3,5-tri-O-benzoyl-5(R,S)-C-ethynyl-B-D-ribofuranosyl)pyrrolo[2,3- djpyrimidine (R/S ratio: 1:1) was prepared from1-O-acethyl-2,3,5-tri-O-benzolyl-5(R,S)-C-
ethynyl-D-ribofuranose and 4-amino-6-bromo-5-cyanopyrrolo[2,3-d]pyrimidine. 4-amino-6- bromo-5-cyano-7-(4-enzoyloxomethyl-2,3,5-tri-O-benzoyl-B-D-ribofuranosyl)pyrrolo[2,3- dipyrimidine was prepared from 1-O-acetyl-4-benzoyloxymethyl-2,3,5-tri-O-benzoyl-D- ribofuranose and 4-amino-6-bromo-5-cyanopyrrolo(2,3-d]pyrimidine. 4-Amino-6-bromo-5- cyano-7-(1,2,3,5-tetra-O-acethyl-5(R)-C-methyl-B-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine was prepared from 1,2,3,5-tetra-O-acethyl-5(R)-C-methyl-D-ribofuranose and 4-amino-6- bromo-5-cyanopyrrolo[2,3-d)pyrimidine. 4-Amino-6-bromo-5-cyano-7-(1,2.3.5-tetra-O- acetyl-5(S)-C-methyl-B-D-ibofuranosyl)pyrrolo[2,3-d]pyrimidine was prepared from 1.2,3,5- tetra-O-acethyl-5(S)-C-methyl-D-ribofuranose and 4-amino-6-bromo-5-cyanopyrrolo(2,3- d]pyrimidine. 4-Amino-6-bromo-5-cyano-7-(2,3-di-O-acetyl-5-deoxy-B-D- ribofuranosyl)pyrrolo[2,3-d]pyrimidine was prepared from 1.2,3-tri-O-acetyl-5-deoxy-D- ribofuranose and 4-amino-6-bromo-5-cyanopyrrolo{2,3-d]pyrimidine. 4-Amino-6-bromo-5- cyano-7-(2,3,5-tri-O-benzoyl-5(R)-C-vinyl-p-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine was prepared from 1-O-acetyl-2,3,5-tri-O-benzoyl-5(R)-C-vinyl-p-D-ribofuranose and 4-amino-6- bromo-5-cyanopyrrolo(2,3-d]pyrimidine.
Preparation of 4-amino-5-cyano-7-(2,3,5-tri-O-benzoyl-5(R)-C-allyl--D- : ribofuranosyl)pyrrolo[2,3-djpyrimidine (20e)
To a solution of 4-amino-6-bromo-5-cyano-7-(2,3,5-tri-O-benzoyl-5(R)-C-allyl-p-D- . ribofuranosyl)pyrrolo[2,3-d]pyrimidine (738 mg 1.0 mmol) in acetic acid (25 mL) was added zinc dust (1.04 g, 16.0 mmol) in two portions (one hour apart). The reaction mixture was stirred at room temperature for 20 h and filtered. The filtrate was evaporated to dryness and the residue chromatographed on silica (ethyl acetate-hexanes 1:1) to give 450 mg of titled compound 20e as a colorless foam. The following compounds were prepared in a similar fashion: 4-Amino-5- cyano-7-(2,3,5-tri-O-benzoyl-5(R,S)-C-ethynyl-B-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine (R/S ratio: 1:1) 20b from 4-amino-6-bromo-5-cyano-7-(2,3,5-tri-O-benzoyl-5(R,S)-C-ethynyl-p-
D-ribofuranosy!)pyrrolo[2,3-d]pyrimidine. 4-Amino-5-cyano-7-(2,3,5-tri-O-benzoyl-5(R)-C- vinyl-B-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine 20¢ from 4-amino-6-bromo-5-cyano-7-(2,3,5- tri-O-benzoyl-5(R)-C-vinyl-B-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine.
Preparation of 4-amino-3-cyano-7-(2,3,5-tri-O-benzoyl-5(R)-C-propyl--D- ribofuranosyl)pyrrolo(2,3-d]pyrimidine (20f) 20 / B
A suspension of 4-amino-6-bromo-5-cyano-7-( 2.3,5-tri-O-benzoy!-5(R)-C-allyl-p-D- ribofuranosyl)pyrrolo[2,3-dJpyrimidine (400 mg, 0.54 mmol) and 10% Pd/C (100 mg, ~50% water) in dioxane (50 mL) and triethylamine (0.5 mL) was shaken in hydrogenation apparatus (Ha, 20 psi) for 4 h. The catalyst was filtered and washed (dioxane). The combined filtrate was concentrated and the residue chromatographed on silica (ethyl acetate-hexanes 1:1) to give 340 mg of the titled compound 20f as a colorless foam. The following compounds were prepared in a similar fashion: 4-Amino-5-cyano-7-(2,3,5-tri-O-benzoyl-5(R,S)-C-ethyl-B-D- ribofuranosyl)pyrrolo[2,3-d}pyrimidine (R/S ratio: 1:1) 20d from 4-amtino-6-bromo-3-cyano-7- (2.3,5-tri-O-benzoyl-5(R,S)-C-ethynyl-B-D-ribofuranosyl)pyrrolo[2.3-d]pyrimidine. 4-Amino-5- cyano-7-(4-benzoyloxomethyl-2,3,5-tri-O-benzoyl-B-D-ribofuranosyl)pyrroio[2.3-d] pyrimidine from 4-amino-6-bromo-5-cyano-7-(4-benzoyloxomethyl-2.3.5-tri-O-benzoyl-p-D- ribofuranosyl)pyrrolo[2.3-d]pyrimidine. 4-Amino-5-cyano-7-(1.2.3.5-tetra-O-acethyl-5(R)-C- methyl-B-D-ribofuranosyl)pyrrolo[2.3-d]pyrimidine 20a from 4-Amino-6-bromo-5-cyano-7- (1,2,3.5-tetra-O-acethyl-5(R)-C-methyl-f-D-ribofuranosyl)pyrrolo[2.3-d]pyrimidine. 4-Amino- 5-cyano-7-(1,2,3,5-tetra-O-acetyl-5(S)-C-methyl-B-D-ribofuranosyl)pyrrolo[2.3-d]pyrimidine 20a from 4-Amino-6-bromo-5-cyano-7-(1,2.3.5-tetra-O-acethyl-5(S)-C-methyl-B-D- ribofuranosyl)pyrrolo[2,3-d]pyrimidine. 4-Amino-5-cyano-7-(1,2,3-tri-O-acethyl-5-deoxy-f-D- ribofuranosyl)pyrrolo[2,3-d]pyrimidine from 4-amino-6-bromo-5-cyano-7-(1,2.3-tri-O-acethyl- 5-deoxi-B-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine. 4-Amino-5-cyano-7-(2,3-dideoxy-B-D- glicero-pentofuranosyl)pyrrolo[2,3-d]pyrimidine was prepared from 4-amino-5-cyano-7-(2,3- dideoxy-B-D-pent-2-enofuranosyl)pyrrolo[2.3-d]pyrimidine.
Preparation of 4-amino-5-cyano-7-(5(R)-C-allyl-§-D-ribofuranosyl)pyrrolo[2, 3-d] pyrimidine (23e)
A solution of 4-amino-5-cyano-7-(2.3,5-tri-O-benzoyl-5(R)-C-allyl-B-D-ribofuranosyl)- pyrrolo[2,3-d}pyrimidine (300 mg, 0.454 mmol) in methanol (40 mL) at 0 °C was saturated with ammonia. The solution stood at room temperature for 2 days. Solvent was evaporated and the residue together with NaOAc (anhydrous, 20 mg) was suspended in DMF (20 mL). The mixture was stirred under argon at 120 °C for 5 h. Solvent was evaporated. The residue was adsorbed onto silica gel and cluted from silica gel column (methanol-ethyl acetate 1:25) to give 145 mg of the titled compound as a colorless solid.
Before heating in DMF, the product contained two major compounds 21 and 23. which coulde be separated by chromatography on silica gel. Compounds 21 were prepared through this procedure. The following compounds were prepared in a similar fashion: 4-Amino-5-cyano-7- (5(R)-C-propyl-B-D-ribofuranosyl)pyrrolo{2,3-d}pyrimidine 23f from 4-amino-5-cyano-7-(2,3.5- tri-O-benzoyl-5(R)-C-propyl-B-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine. 4-Amino-5-cyano-7- (5(R,S)-C-ethynyl-B-D-ribofuranosyl)pyrrolo[2.3-d]pyrimidine (R-S ratio: 1:1) 23b from 4-amino-5-cyano-7-(2,3,5-tri-O-benzoyl-5(R.S)-C-ethynyl-B-D-ribofuranosyl)pyrrolo[2,3-d]pyr- imidine. 4-Amino-5-cyano-7-(5(R.,S)-C-ethyl-B-D-ribofuranosyl)pyrrolo[2,3-d}pyrimidine (R-S ratio: 1:1) 23d from 4-amino-5-cyano-7-(2.3,5-tri-O-benzoyl-5(R,S)-C-ethyl-B-D-ribofuranos- ybpyrrolo[2,3-d]pyrimidine. 4-Amino-5-cyano-7-(4-hydroxymethyl-B-D-ribofuranosyl)pyrrolo- [2,3-d]pyrimidine 33d from 4-Amino-5-cyano-7-(4-benzoyloxomethyl-2,3,5-tri-O-benzoyl-B-D- ribofuranosyl)pyrrolo[2,3-d]pyrimidine. 4-Amino-5-cyano-7-(5(R)-C-methyl-B-D-ribofuranos- yDpyrrolo[2,3-d]pyrimidine 23a(5’-R) from 4-amino-5-cyano-7-(1 ,2,3,5-tetra-O-acethyl-5(R)-C- methyl-B-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine. 4-Amino-5-cyano-7-(5(S)-C-methyl-f-D- ribofuranosyl)pyrrolo[2,3-djpyrimidine 23a(5’-S) from 4-amino-5-cyano-7-(1,2.3.5-tetra-O- acethyl-5(S)-C-methyl-B-D-ribofuranosyl)pyrrolo[2.3-d]pyrimidine. 4-Amino-5-cyano-7-(5- deoxy-B-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine 10 from 4-amino-5-cyano-7-(1,2,3-tri-O- acethyl-5-deoxi-B-D-ribofuranosyl)pyrrolo{2,3-d]pyrimidine. 4-Amino-5-cyano-7-(5(R)-C- vinyl-B-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine 23c from 4-amino-5-cyano-7-(2,3.5-tri-O- benzoyl-5(R)-C-vinyl-B-D-ribofuranosyl)pyrrolo-[2,3-d]pyrimidine.
Preparation of 4-amino-3-cyano-7-(2,3-di-O-methanesulfonyl-5-O-tert-butyldiphenylsilyl--D- ribofuranosyl)pyrrolof2,3-d]pyrimidine
To a stirred solution of toyocamicin 43 (5.83 g, 20.0 mmol) in anhydrous pyridine (100 mL) at 0°C was added fers-butylchlorodiphenyisilane (6.2 mL, 24.0 mmol). The resulting mixture was stirred at room temperature for 18 h and then cooled to 0°C, and methanesulfonyl chloride (3.4 mL, 44.0 mmol) was added. The resulting mixture was stirred at room temperature for 2 h, cooled with ice, quenched by adding water (2 mL), and stirred at room temperature for min. The solvent was evaporated. The residue was dissolved in ethyl acetate, washed with 30 brine three times, dried (Na,SO,) and concentrated. Chromatography on silica (ethyl acetatehexanes 3:2) gave 8.41 g of the titled compound as a colorless solid. 22 b oo
: | wo 01/27114 PCT/US00/22674
Preparation of 4-amino-3-cyano- 7-(5-O-tert-butvidiphenylsilyl-2. 3-didehydro-2. 3-dideoxy-3-D- ribofuranosyljpyrrolo(2.3-d]pyrimidine
Tellurium powder (200 mesh. 640 mg 5.0 mmol) under argon was sealed, mixed with lithium triethylborohydrate (1.0 M in THF, 11.25 mL. 11.25 mmol). The mixture was stirred at room temperature for 6 h and then cooled to 5 °C, and 4-amino-5-cyano-7-(2.3-di-O- methanesulfonyl-5 -O-tert-butyldiphenyisilyl-B-D-ribofuranosyl)pyrrolo[2.3-d]pyrimidine (1.40 g, 2.09 mmol) in THF (12 mL) was added. The resulting mixture was stirred at room temperature for 18 h, cooled with ice. quenched by adding water (0°C. 5 mL). and stirred at room temperature for 30 min. Solvent was evaporated and the residue extracted with ethyl acetate. The extracts were concentrated and the residue chromatographed on silica (15% ethyl acetate in hexanes) to give 640 mg of the titled compound as a colorless foam.
Preparation of 4-amino-3-cyano-7-(2,3-didehydro-2, 3-dideoxy-f-D- ribofuranosyl)pyrrolo[2,3- d]pyrimidine (49)
To a stirred solution of 4-amino-5-cyano-7-(5-O-fert-butyldiphenylsilyl-2.3-didehydro- 2,3-dideoxy-f-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine (2.55 g, 5.32 mmol) in anhydrous THF (100 mL) at 5 °C was added terabutylammonium fluoride (1.0 M in THF, 6.6 mL). The resulting mixture was stirred at room temperature for 3 h and concentrated. Chromatography on silica (6% methanol in ethyl acetate) gave 1.09 g of the titled compound 49 as a colorless solid.
Preparation of 5-cyvano-7-(5(R)-C-methyl-f-D-ribofuranosyl)pyrrolo[2.3-d]-+-pyrimidone (25a)
To a stirred solution of 4-amino-5-cyano-7-(5(R)-C-methyl-B-D-ribofuranosyl)-pyrrolo- [2.3-d}pyrimidine (306 mg, 1.0 mmol) in water (30 mL) and acetic acid (2.0 mL) at 55 °C was added in portions sodium nitrite (590 mg, 8.55 mmol). The resulting mixture was stirred at 70 ° C for 3 h and more sodium nitrite (300 mg, 4.30 mmol) was added. The mixture was stirred at same temperature for additional 18 h. Solvent was evaporated and the residue chromatographed on silica (12 % methanol in methylene chloride) to give 210 mg of the titled compound 25a(5’-R) as a colorless solid. Similarly, the following compounds were prepared: 4-Amino-5- cyano-7-(5(S)-C-methyl-B-D-ribofuranosyl)pyrrolo[2,3-d]-4-pyrimidone 25a(5°-S) from 4-amino-5-cyano-7-(5(S)-C-methyl-B-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine. 4-Amino-5- cyano-7-(p-D-arabinofuranosyl)pyrrolo[2,3-d]-4-pyrimidone 58 from 4-amino-5-cyano-7- (5-deoxi-B-D-arabinofuranosy)pyrrolo[2,3-d]pyrimidine. 4-Amino-5-cyano-7-(5-deoxy-B-D- ribofuranosyl)pyrrolo[2,3-d]-4-pyrimidone 11 from 4-amino-5-cyano-7-(5-deoxy-p-D-
ribofuranosyl)pyrrolo[2,3-d]pyrimidine. 4-Amino-5-cyano-7-(2,3-dideoxy-2,3-didehydro-8-D- glycero-pento-furanosyl) pyrrolo{2,3-d}-4-pyrimidone 50 from 4-amino-5-cyano-7-(2,3-dideoxy-
B-D-pent-2-enofuranosyl)pyrrolo-[2,3-d}pyrimidine. 4-Amino-5-cyano-7-(2,3-dideoxy-g-D- glycero-pentofuranosyl)pyrrolo{2,3-d]-4-pyrimidone 65 from 4-amino-5-cyano-7-(2,3-dideoxy-p -D-glycero-pentofuranosyl)pyrrolo[2,3-d]pyrimidine. 4-Amino-5-cyano-7-(2-deoxy-B-D- furanosyl)pyrrolo(2,3-d}-4-pyrimidone 69 from 4-amino-5-cyano-7-(2-deoxy-p-D- eritropentofuranosyl)pyrrolo[2,3-d]pyrimidine.
Preparation of 7-(5(R)-C-methyl-3-D-ribofuranosyl)pyrrolo[2, 3-d]-4-pyrimidone-3- carboxamidoxime (24a)
A stirred suspension of 5-cyano-7-(5(R)-C-methyl-B-D-ribofuranosyl)pyrrolo[2,3-d}-4- pyrimidone (240 mg, 0.784 mmol), hydroxylamine hydrochloride (163 mg, 2.352 mmol), and potassim carbonate (162 mg, 1.176 mmol) in ethanol (50 mL) was refluxed under argon for 18 h.
Preciptate was filtered and washed with warm ethanol. The filtrate was concentrated and the residue chromatographed on silica (20 % methanol in methylene chloride) to give 170 mg of the titled compound 26a(5’-R) as a colorless solid. Similarly, the following compounds were prepared: 4-Amino-5-cyano-7-(B-D-arabinofuranosyl)pyrrolo[2,3-d]-4-pyrimidone-5- : carboxamidoxime 60 from 4-amino-5-cyano-7-(5-deoxi-B-D-arabinofuranosy)-pyrrolo[2,3-d]-4- pyrimidone. } 4-Amino-5-cyano-7-(5-deoxy-B-D-ribofuranosyl)pyrrolo[2,3-d]-4-pyrimidone-5-carbox- amidoxime 13 from 4-amino-5-cyano-7-(5-deoxy-B-D-ribofuranosyl)pyrrolo{2,3-d]-4- pyrimidone. 4-Amino-5-cyano-7-(2,3-didehydro-2,3-dideoxy-p-D-ribofuranosyl)pyrrolo[2,3-d]- 4-pyrimidone-5-carboxamidoxime 51 from 4-amino-5-cyano-7-(2,3-didehydro-2,3-dideoxy-B-D- ribofuranosyl)pyrrolo[2,3-d)-4-pyrimidone. 4-Amino-5-cyano-7-(2-deoxy-p-D- ribofuranosyl)pyrrolo[2,3-d]-4-pyrimidone-5-carboxamidoxime from 4-amino-5-cyano-7-(2- deoxy-f3-D-ribofuranosyl)pyrrolo(2,3-d]-4-pyrimidone.
Preparation of 7-(5(R)-C-methyl-f-D-ribofuranosyl)pyrrolo[2, 3-d]-4-pyrimidone-3- carboxamidine hydrochloride (27a) :
A suspension of 7-(5(R)-C-methyl-B-D-ribofuranosyl)pyrrolo[2,3-d]-4-pyrimidone-5- carboxamidoxime (110 mg, 0.324 mmol), ammonium chloride (20 mg, 0.374 mmol), and Raney nickel (50% slurry in water, 200 mg) in water (75 mL) was shaken in a hydrogenation apparatus (H,., 50 psi) at room temperature for 18 h. The catalyst was filtered and washed (warm water). 24 ps
The combined filtrate was concentrated and the product was recrystallized from methanol to give 100 mg of the titled compound 27a(5’-R) as a colorless solid. The following compounds were prepared in similar fashion: 4-Amino-5-cyano-7-(B-D-arabinofuranosyl)pyrrolo[2,3-d]-4- pyrimidone-5-carboxamidine hydrochloride 63 from 4-amino-5-cyano-7-(5-deoxi-p-D- arabinofuranosy)pyrrolo[2,3-d}-4-pyrimidone-5-carboxamidoxime. 4-Amino-5-cyano-7-(5- deoxy-f-D-ribofuranosyl)pyrrolo[2,3-d}-4-pyrimidone-5-carboxamidine hydrochloride 15 from 4-amino-5-cyano-7-(5-deoxi-B-D-ribofuranosyl)pyrroio[2,3-d]-4-pyrimidone-5- carboxamidoxime. 4-Amino-5-cyano-7-(2-deoxy-B-D-ribofuranosyl)pyrrolo{2,3-d}-4- pyrimidone-5-carboxamidine hydrochloride 70 from 4-amino-5-cyano-7-(2-deoxy-f-D- ribofuranosyl)pyrrolo[2,3-d]-4-pyrimidone-5-carboxamidoxime.
Thus. specific embodiments and applications of pyrrolo[2,3-d]pyrimidine nucleoside analogs have been disclosed. It should be apparent. however. to those skilled in the art that many more modifications besides those already described are possible without departing from the inventive concepts herein. The inventive subject matter. therefore. is not to be restricted except in the spirit of the appended claims. Moreover, in interpreting both the specification and . the claims, all terms should be interpreted in the broadest possible manner consistent with the context. In particular, the terms “comprises” and “comprising” should be interpreted as referring to elements, components, or steps in a non-exclusive manner. indicating that the referenced elements, components, or steps may be present, or utilized, or combined with other elements. components, or steps that are not expressly referenced.
Claims (33)
1. A nucleoside analog according to formula (I): Xz 0 v SN N
Rs. ID, Rs~ | A ot Ry RR; wherein A is O, S, or CH,; Xis H, NH, or OH; Y is H, halogen or NH,; C* is directed in beta orientation and is a secondary carbon atom covalently bound to an oxygen atom or phosphorus atom; Z is selected from the group consisting of H, halogen, R, OH, OR, SH, SR, NH, NHR, NR;, CN, C(O)NH,, COOH, COOR, CH,NH,, C(=NOH)NH,, and C(=NH)NH,, where R is alkyl, alkenyl, alkynyl, or aralkyl; R, and Rj are independently selected from the group consisting of H, F, and OH; Ry is selected from the group consisting of a hydrogen, an alkyl, an alkenyl, an alkynyl, and an aralkyl, wherein R4 optionally has at least one of a heteroatom and a functional group; Co Rs is OH, OP(O)(OH),, P(O)(OH),, OP(O)(OR'),, or P(O)(OR"),, wherein R'is a masking group; and Rs is selected from the group consisting of an alkyl, an alkenyl, an alkynyl, and an aralkyl, wherein Rs has at least two carbon atoms, and optionally has at least one of a heteroatom and a functional group.
2. The nucleoside analog of claim 1 wherein Z is CN, C(O)NH,, or C(=NH)NH,, and wherein Rs has at least two carbon atoms and is selected from the group consisting of an alkyl, an alkenyl, an alkynyl, and an aralkyl.
oo F WUS00/2267, Attorney Reference No.: 330.48-PCT IP EA/US 25 M AR 2001
3. The nucleoside analog of claim 1 having the structure QO z TI NS N Re N Rs’ o Ry Ry Ry wherein Z is CN, C(O)NH,, C(=NH)NH,, or C(=NOH)NHj; and Ry and Ry are independently selected from the group consisting of a hydrogen, an 0) alkyl, an alkenyl, an alkynyl, and an aralkyl, wherein R4 and Rs independently and optionally contain at least one of a heteroatom and a functional group; with the proviso that R4 and Rs are not together hydrogen.
:
4. A method of changing secretion of a cytokine from a cell, comprising: providing a compound according to formula (II); and X z N ’d rd Po y” NT NAD) Rs Rs’ A R, Ry Ry wherein A is O, S, or CH; X is H, NH; or OH; Y is H, halogen or NH»; Z is selected from the group consisting of H, halogen, R, OH, OR, SH, SR, NH,, NHR, NR», CN, C(O)NH,, COOH, COOR, CH,NH,, C(=NOH)NH,, and C(=NH)NH,, where R is alkyl, alkenyl, alkynyl, or aralkyl; R, and Rj; are independently selected from the group consisting of H, F, and OH; 27 SMEDED SHEET
Co oo So y P Attorney Reference No.: 330.48-PCT S0n/2267, Y Reterence No. 48- IP EAIUS 2.6 MAR 2001 R4 and Ry are independently selected from the group consisting of a hydrogen, an alkyl, an alkenyl, an alkynyl, and an aralkyl, and wherein R4 and Rs: independently and optionally contain at least one of a heteroatom and a functional group; Rs is H, OH, OP(O)(OH),, P(O)(OH),, OP(O)(OR'),, or P(O)(OR'), wherein R'is a masking group; and presenting the cell with the compound at a concentration effective to change the secretion of the cytokine.
5. The method of claim 4 wherein the cytokine is a Type 1 cytokine.
6. The method of claim 5 wherein the Type 1 cytokine is IFNy.
®
7. The method of claim 4 wherein the cytokine is a Type 2 cytokine.
8. The method of claim 7 wherein the Type 2 cytokine is IL-4. . 0.
The method of claim 4 wherein the cell is a lymphocyte.
10. The method of claim 4 wherein the cell is a cancer cell.
11. The method of claim 10 wherein the cancer cell is a prostate cancer cell.
12. A method of changing secretion of a cytokine from a cell, comprising: o providing a compound according to formula (IIT) oO z CI SN ON (IID) HO OH wherein Z is CN, C(O)NH,, C(=NH)NH,, C(=NNH;)NH,, or -C(=NOH)NHj, 28
A .
Attorney Reference No.: 330.48-PCT IPEA/US 0 / / 4 26 MAR 2001 wherein Rs is H, OH, OP(O)(OH),, P(O)(OH),, OP(O)(OR),, or P(O)(OR"), wherein R'is a masking group; and presenting the cell with the compound at a concentration effective to change the secretion of the cytokine.
13. A method of reducing growth of a hyperproliferative cell, comprising: providing a compound according to formula (IV) 1; X z jon v7" SN TN (Iv) J Rs Ry' A Ry Ry Ry wherein A is O, S, or CH,; X is H, NH; or OH; Y is H, halogen or NH»; Z is selected from the group consisting of H, halogen, R, OH, OR, SH, SR, NH,, NHR, NR;, CN, C(O)NH,, COOH, COOR, CH,NH;, C(=NOH)NH,, and C(=NH)NH,, where R is alkyl, alkenyl, alkynyl, or aralkyl; O R, and Rj are independently selected from the group consisting of H, F, and OH; R, is selected from the group consisting of a hydrogen, an alkyl, an alkenyl, an alkynyl, and an aralkyl, wherein R4 optionally contains at least one of a heteroatom and a functional group; Rs is selected from the group consisting of a hydrogen, an alkyl, an alkenyl, an alkynyl, and an aralkyl, wherein Rs has at least two carbon atoms, and optionally contains at least one of a heteroatom and a functional group; Rs is H, OH, OP(O)(OH),, P(O)(OH),, OP(O)(OR),, or P(O)(OR'),, wherein R' is a masking group, with the proviso that R4 and Rs are not together hydrogen; and 29 AMENDED SHEET a. Co ‘ PCT/US00/22674 presenting the hyperproliferative cell with the compound at a concentration effective to reduce the growth of the hyperproliferative cell.
14. The method of claim 13 wherein the hyperproliferative cell is a cancer cell.
15. The method of claim 14 wherein the cancer cell is a prostate cancer cell.
16. The method of claim 13 wherein the reduction of growth comprises reduction of DNA synthesis.
17. A method of reducing a release of a growth factor from a cell, comprising: providing a compound according to claim 1; and presenting the cell with the compound at a concentration effective to reduce the release of the growth factor.
18. The method of claim 17 wherein the growth factor is VEGF.
19. The method of claim 17 wherein the cell is a cancer cell.
20. The method of claim 19 wherein the cancer cell is a prostate cancer cell.
21. Use of a compound as defined in claim 4 in the manufacture of a preparation for changing secretion of a cytokine from a cell, by presenting the cell with the compound at a concentration effective to change the secretion of the cytokine.
22. Use of a compound as defined in claim 12 in the manufacture of a preparation for changing secretion of a cytokine from a cell, by presenting the cell with the compound at a concentration effective to change the secretion of the cytokine. AMENDED SHEET
4 PCT/US00/22674
23. Use of a compound according to claim 13 in the manufacture of a preparation for reducing growth of a hyperproliferative cell, by presenting the hyperproliferative cell with the compound at a concentration effective to reduce the growth of the hyperproliferative cell.
24. Use of a compound according to claim 1 in the manufacture of a preparation for reducing a release of a growth factor from a cell by presenting the cell with the compound at a concentration effective to reduce the release of the growth factor.
25. A substance or composition for use in a method of changing secretion of a cytokine from a cell, said substance or composition comprising a compound according to claim 4, and said method comprising presenting the cell with the compound at a concentration effective to change the secretion of the cytokine.
26. A substance or composition for use in a method of changing secretion of a cytokine from a cell, said substance or composition comprising a compound according to claim 12, and said method comprising presenting the cell with the compound at a concentration effective to change the secretion of the cytokine.
27. A substance or composition for use in a method of reducing growth of a hyperproliferative cell, said substance or composition comprising a compound according to claim 13, and said method comprising presenting the hyperproliferative cell with the compound at a concentration effective to reduce the growth of a hyperproliferative cell.
28. A substance or composition for use in a method of reducing a release of a growth factor from a cell, said substance or composition comprising a compound according to claim 1, and said method comprising presenting the cell with the compound at a concentration effective to reduce the release of the growth factor. 31 i AMENDED SHEET
/ PCT/US00/22674
29. A nucleoside analog according to claim 1, substantially as herein described and illustrated.
30. A non-therapeutic method of treatment according to claim 4, or claim 12, or claim 13, or claim 17, substantially as herein described and illustrated.
31. Use according to claim 21, or claim 22, or claim 23, or claim 24, substantially as herein described and illustrated.
32. A substance or composition for use in a method of treatment according to claim 25, or claim 26, or claim 27, or claim 28, substantially as herein described and illustrated.
33. A new nucleoside analog, a new non-therapeutic method of treatment, a new use according to any one of claims 21 - 24, or a substance or composition for a new use in a method of treatment, substantially as herein described. 32 AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15123399P | 1999-08-27 | 1999-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200201567B true ZA200201567B (en) | 2003-07-30 |
Family
ID=22537871
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200201567A ZA200201567B (en) | 1999-08-27 | 2002-02-25 | Pyrrolo[2,3-d]pyrimidine nucleoside analogs. |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1212326A4 (en) |
JP (1) | JP2003511454A (en) |
KR (1) | KR20020092904A (en) |
CN (1) | CN1384834A (en) |
AU (1) | AU769578B2 (en) |
BR (1) | BR0013642A (en) |
CA (1) | CA2381297A1 (en) |
HR (1) | HRP20020163A2 (en) |
HU (1) | HUP0301875A2 (en) |
IL (1) | IL147908A0 (en) |
MX (1) | MXPA02001753A (en) |
NO (1) | NO20020931D0 (en) |
PL (1) | PL354094A1 (en) |
RU (1) | RU2002103501A (en) |
SI (1) | SI20819A (en) |
SK (1) | SK1772002A3 (en) |
WO (1) | WO2001027114A1 (en) |
ZA (1) | ZA200201567B (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6455508B1 (en) * | 2000-02-15 | 2002-09-24 | Kanda S. Ramasamy | Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides |
US7638496B2 (en) | 2000-02-15 | 2009-12-29 | Valeant Pharmaceuticals North America | Nucleoside analogs with carboxamidine modified monocyclic base |
JP2003183283A (en) * | 2001-12-18 | 2003-07-03 | Takeda Chem Ind Ltd | Condensed indole compound, method for producing the same and application of the same |
US20050182252A1 (en) | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
CN101851241B (en) * | 2010-07-02 | 2012-05-23 | 西安交通大学 | Anti-tumor compound and preparation method and application thereof |
KR20130110170A (en) | 2010-09-22 | 2013-10-08 | 앨리오스 바이오파마 인크. | Substituted nucleotide analogs |
CN102286048A (en) * | 2011-06-24 | 2011-12-21 | 吉林大学 | 4-amino-6-(3-(3-bromophenyl) phenyl-5-cyano-7-(beta-L-xylofuranose) pyrrolo [2,3-d] pyrimidine, like derivatives and application for preparing antitumor drugs |
US8980865B2 (en) | 2011-12-22 | 2015-03-17 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
LT2794627T (en) | 2011-12-22 | 2019-01-10 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
CN104321333A (en) | 2012-03-21 | 2015-01-28 | 沃泰克斯药物股份有限公司 | Solid forms of a thiophosphoramidate nucleotide prodrug |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
NZ630805A (en) | 2012-03-22 | 2016-01-29 | Alios Biopharma Inc | Pharmaceutical combinations comprising a thionucleotide analog |
AU2015217221A1 (en) | 2014-02-13 | 2016-08-11 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
WO2016003812A1 (en) | 2014-07-02 | 2016-01-07 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and uses therof |
AR104326A1 (en) | 2015-05-04 | 2017-07-12 | Lilly Co Eli | 5-SUBSTITUTED NUCLEOSID COMPOUNDS |
KR102185996B1 (en) * | 2015-09-23 | 2020-12-02 | 머크 샤프 앤드 돔 코포레이션 | 4'-substituted nucleoside reverse transcriptase inhibitor and preparation method thereof |
CN111788196A (en) | 2018-01-09 | 2020-10-16 | 配体药物公司 | Acetal compounds and their therapeutic use |
BR112019027944A2 (en) * | 2018-05-15 | 2020-12-01 | Illumina, Inc. | compositions and methods for chemically cleaving and deprotecting surface-bound oligonucleotides |
WO2020205867A1 (en) | 2019-04-02 | 2020-10-08 | Aligos Therapeutics, Inc. | Compounds targeting prmt5 |
KR102639275B1 (en) * | 2021-06-08 | 2024-02-21 | 퓨쳐메디신 주식회사 | Nucleoside derivative having kinase multiple target inhibiting activity and pharmaceutical composition for preventing and treating cancer comprising the same |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3988338A (en) * | 1974-04-24 | 1976-10-26 | Wisconsin Alumni Research Foundation | 4-Substituted amino-2-substituted thio-pyrrolo-[2,3-d]pyrimidine derivatives |
US4892865A (en) * | 1987-12-01 | 1990-01-09 | The Regents Of The University Of Michigan | Pyrrolo[2,3-d]pyrimidine nucleosides as antiviral agents |
US5674998A (en) * | 1989-09-15 | 1997-10-07 | Gensia Inc. | C-4' modified adenosine kinase inhibitors |
AU673055B2 (en) * | 1993-02-03 | 1996-10-24 | Gensia, Inc. | Adenosine kinase inhibitors comprising lyxofuranosyl derivatives |
US5665721A (en) * | 1995-06-07 | 1997-09-09 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
DE69729887T2 (en) * | 1996-10-16 | 2005-07-28 | ICN Pharmaceuticals, Inc., Costa Mesa | Purine L nucleosides, analogs and their use |
-
2000
- 2000-08-17 IL IL14790800A patent/IL147908A0/en unknown
- 2000-08-17 JP JP2001530332A patent/JP2003511454A/en not_active Withdrawn
- 2000-08-17 SK SK177-2002A patent/SK1772002A3/en unknown
- 2000-08-17 PL PL00354094A patent/PL354094A1/en not_active Application Discontinuation
- 2000-08-17 KR KR1020027002570A patent/KR20020092904A/en not_active Application Discontinuation
- 2000-08-17 SI SI200020035A patent/SI20819A/en not_active IP Right Cessation
- 2000-08-17 EP EP00959267A patent/EP1212326A4/en not_active Withdrawn
- 2000-08-17 WO PCT/US2000/022674 patent/WO2001027114A1/en not_active Application Discontinuation
- 2000-08-17 CA CA002381297A patent/CA2381297A1/en not_active Abandoned
- 2000-08-17 AU AU70618/00A patent/AU769578B2/en not_active Ceased
- 2000-08-17 CN CN00814992A patent/CN1384834A/en active Pending
- 2000-08-17 HU HU0301875A patent/HUP0301875A2/en unknown
- 2000-08-17 BR BR0013642-5A patent/BR0013642A/en not_active IP Right Cessation
- 2000-08-17 MX MXPA02001753A patent/MXPA02001753A/en unknown
- 2000-08-17 RU RU2002103501/04A patent/RU2002103501A/en not_active Application Discontinuation
-
2002
- 2002-02-22 HR HR20020163A patent/HRP20020163A2/en not_active Application Discontinuation
- 2002-02-25 ZA ZA200201567A patent/ZA200201567B/en unknown
- 2002-02-26 NO NO20020931A patent/NO20020931D0/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2002103501A (en) | 2003-09-10 |
AU769578B2 (en) | 2004-01-29 |
EP1212326A4 (en) | 2003-08-20 |
JP2003511454A (en) | 2003-03-25 |
SI20819A (en) | 2002-08-31 |
HRP20020163A2 (en) | 2004-02-29 |
PL354094A1 (en) | 2003-12-29 |
CN1384834A (en) | 2002-12-11 |
IL147908A0 (en) | 2002-08-14 |
BR0013642A (en) | 2002-05-07 |
NO20020931L (en) | 2002-02-26 |
EP1212326A1 (en) | 2002-06-12 |
AU7061800A (en) | 2001-04-23 |
HUP0301875A2 (en) | 2003-09-29 |
CA2381297A1 (en) | 2001-04-19 |
NO20020931D0 (en) | 2002-02-26 |
MXPA02001753A (en) | 2002-10-23 |
KR20020092904A (en) | 2002-12-12 |
SK1772002A3 (en) | 2002-10-08 |
WO2001027114A1 (en) | 2001-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU769578B2 (en) | Pyrrolo(2,3-d)pyrimidine nucleoside analogs | |
EP1660511B1 (en) | Novel tricyclic nucleosides or nucleotides as therapeutic agents | |
US6831069B2 (en) | Pyrrolo[2,3-d]pyrimidine nucleoside analogs | |
KR100811927B1 (en) | Nucleoside analogs with carboxamidine modified monocyclic base | |
KR20030032944A (en) | Pyrido [2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides | |
US5384310A (en) | 2'-fluoro-2-haloarabinoadinosines and their pharmaceutical compositions | |
Bhat et al. | Pyrazolopyrimidine nucleosides. 12. Synthesis and biological activity of certain pyrazolo [3, 4-d] pyrimidine nucleosides related to adenosine | |
KR20030061792A (en) | Nucleoside derivatives | |
KR20000049181A (en) | Purine l-nucleosides, analogs and uses thereof | |
AU2001273670A1 (en) | Pyrido(2,3-d)pyrimidine and pyrimido(4,5-d)pyrimidine nucleosides | |
WO2004080466A1 (en) | Cytidine analogs and methods of use | |
Bussolari et al. | Synthesis and biological evaluation of N4-substituted imidazo-and v-triazolo [4, 5-d] pyridazine nucleosides | |
Baker et al. | An evaluation of certain chain-extended analogs of 9-. beta.-D-arabinofuranosyladenine for antiviral and cardiovascular activity | |
Zou et al. | Synthetic approaches to the guanosine and xanthosine analogs 5-amino-3-. beta.-D-ribofuranosylpyrazolo [3, 4-e][1, 3] oxazin-7-one and 3-. beta.-D-ribofuranosylpyrazolo [3, 4-e][1, 3] oxazine-5, 7-dione and studies of their antitumor potential |